{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T06:20:10Z","timestamp":1773382810026,"version":"3.50.1"},"reference-count":16,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p>Lewy body dementia (LBD) is a progressive neurological disorder characterized by dementia, parkinsonism, and psychotic symptoms. Treating psychosis in LBD is particularly challenging, especially given the high risk of extrapyramidal effects of antipsychotics commonly associated with this population. If treatment with an antipsychotic is warranted, low-potency antipsychotics are preferred; however, they may not be suitable for all patients because of adverse effect profiles, safety concerns, or logistical barriers. This case study illustrates how a patient diagnosed with LBD and unable to tolerate or access commonly used antipsychotics was effectively treated with low-dose loxapine.<\/jats:p>","DOI":"10.9740\/mhc.2025.10.252","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:33:23Z","timestamp":1759322003000},"page":"252-254","source":"Crossref","is-referenced-by-count":1,"title":["Loxapine for the treatment of psychosis in Lewy body dementia: A case report"],"prefix":"10.9740","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9542-740X","authenticated-orcid":true,"given":"Leslie","family":"Wu","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Practitioner, Jesse Brown VAMC, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2317-5586","authenticated-orcid":true,"given":"Archana","family":"Jhawar","sequence":"additional","affiliation":[{"name":"(Corresponding author) Clinical Assistant Professor, University of Illinois Chicago Retzky College of Pharmacy, Chicago, Illinois; Clinical Pharmacy Practitioner, Jesse Brown VAMC, Chicago, Illinois, archanaj@uic.edu"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4719","reference":[{"issue":"16","key":"i2168-9709-15-5-252-b01","series-title":"JAMA","first-page":"1589","article-title":"Diagnosis and management of dementia: review","volume":"322","author":"Arvanitakis","year":"2019","unstructured":"Arvanitakis Z,\nShah RC,\nBennett DA. Diagnosis and management of dementia: review. JAMA. 2019;322(16):1589-99. DOI: 10.1001\/jama.2019.4782"},{"key":"i2168-9709-15-5-252-b02","series-title":"StatPearls","article-title":"Behavioral and psychological symptoms in dementia","author":"Cloak","year":"2025","unstructured":"Cloak N,\nSchoo C,\nAl Khalili Y. Behavioral and psychological symptoms in dementia. In: StatPearls. StatPearls Publishing: 2025."},{"key":"i2168-9709-15-5-252-b03","author":"MedlinePlus [Internet]","unstructured":"MedlinePlus [Internet]. Bethesda (MD): National Library of Medicine (US); [updated 2020 Jun 24]. Dementia with Lewy bodies; [updated 2021 Nov 24; viewed 2025 Apr 21]. Available from: https:\/\/medlineplus.gov\/genetics\/condition\/dementia-with-lewy-bodies\/."},{"issue":"10","key":"i2168-9709-15-5-252-b04","series-title":"Am J Psychiatry","first-page":"1491","article-title":"Presentation and management of psychosis in Parkinson\u2019s disease and dementia with Lewy bodies","volume":"164","author":"Weintraub","year":"2007","unstructured":"Weintraub D,\nHurtig HI. Presentation and management of psychosis in Parkinson\u2019s disease and dementia with Lewy bodies. Am J Psychiatry. 2007;164(10):1491-8. DOI: 10.1176\/appi.ajp.2007.07040715"},{"key":"i2168-9709-15-5-252-b05","series-title":"J Clin Psychiatry","first-page":"16","article-title":"Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms","volume":"65 Suppl 11","author":"Baskys","year":"2004","unstructured":"Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004;65 Suppl 11:16-22. PMID: 15264967"},{"key":"i2168-9709-15-5-252-b06","article-title":"Package insert. Hospira, Inc","author":"Naloxone hydrochloride injection, USP","year":"2019","unstructured":"Naloxone hydrochloride injection, USP. Package insert. Hospira, Inc.; 2019."},{"issue":"12","key":"i2168-9709-15-5-252-b07","series-title":"Neurology","first-page":"1863","article-title":"Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium","volume":"65","author":"McKeith","year":"2005","unstructured":"McKeith IG,\nDickson DW,\nLowe J,\nEmre M,\nO\u2019Brien JT,\nFeldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863-72. Erratum in: Neurology. 2005;65(12):1992. DOI: 10.1212\/01.wnl.0000187889.17253.b1"},{"key":"i2168-9709-15-5-252-b08","series-title":"Behav Neurol","first-page":"4938154","article-title":"The efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with Parkinson\u2019s disease","volume":"2016","author":"Divac","year":"2016","unstructured":"Divac N,\nStojanovi\u0107 R,\nSavi\u0107 Vujovi\u0107 K,\nMedi\u0107 B,\nDamjanovi\u0107 A,\nProstran M. The efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with Parkinson\u2019s disease. Behav Neurol. 2016;2016:4938154. DOI: 10.1155\/2016\/4938154"},{"issue":"17","key":"i2168-9709-15-5-252-b09","series-title":"Neurology","first-page":"1356","article-title":"Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism","volume":"68","author":"Kurlan","year":"2007","unstructured":"Kurlan R,\nCummings J,\nRaman R,\nThal L, Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68(17):1356-63. DOI: 10.1212\/01.wnl.0000260060.60870.89"},{"issue":"4","key":"i2168-9709-15-5-252-b10","series-title":"J Integr Neurosci","first-page":"80","article-title":"Clearing the fog: a review of antipsychotics for parkinson's-related hallucinations: a focus on pimavanserin, quetiapine and clozapine","volume":"23","author":"Abdul-Rahman","year":"2024","unstructured":"Abdul-Rahman T,\nHerrera-Calder\u00f3n RE,\nAderinto N,\nKundu M,\nWireko AA,\nAdebusoye FT, et al. Clearing the fog: a review of antipsychotics for parkinson's-related hallucinations: a focus on pimavanserin, quetiapine and clozapine. J Integr Neurosci. 2024;23(4):80. DOI: 10.31083\/j.jin2304080"},{"key":"i2168-9709-15-5-252-b11","series-title":"Am J Case Rep","first-page":"e939806","article-title":"Pimavanserin treatment for psychosis in patients with dementia with Lewy bodies: a case series","volume":"24","author":"Rothenberg","year":"2023","unstructured":"Rothenberg KG,\nMcRae SG,\nDominguez-Colman LM,\nShutes-David A,\nTsuang DW. Pimavanserin treatment for psychosis in patients with dementia with Lewy bodies: a case series. Am J Case Rep. 2023;24:e939806. DOI: 10.12659\/AJCR.939806"},{"key":"i2168-9709-15-5-252-b12","series-title":"Am J Case Rep","first-page":"e937397","article-title":"Neuroleptic sensitivity in dementia with Lewy body and use of pimavanserin in an inpatient setting: a case report","volume":"23","author":"Abadir","year":"2022","unstructured":"Abadir A,\nDalton R,\nZheng W,\nPincavitch J,\nTripathi R. Neuroleptic sensitivity in dementia with Lewy body and use of pimavanserin in an inpatient setting: a case report. Am J Case Rep. 2022;23:e937397. DOI: 10.12659\/AJCR.937397"},{"issue":"10","key":"i2168-9709-15-5-252-b13","series-title":"Cureus","first-page":"e46356","article-title":"Pimavanserin use in Lewy body dementia: a case report demonstrating the medication\u2019s efficacy","volume":"15","author":"Baker","year":"2023","unstructured":"Baker M,\nSong W,\nFusick A. Pimavanserin use in Lewy body dementia: a case report demonstrating the medication\u2019s efficacy. Cureus. 2023;15(10):e46356. DOI: 10.7759\/cureus.46356"},{"key":"i2168-9709-15-5-252-b14","series-title":"Ann Gen Psychiatry","first-page":"15","article-title":"Revisiting loxapine: a systematic review","volume":"14","author":"Popovic","year":"2015","unstructured":"Popovic D,\nNuss P,\nVieta E. Revisiting loxapine: a systematic review. Ann Gen Psychiatry. 2015;14:15. DOI: 10.1186\/s12991-015-0053-3"},{"issue":"4","key":"i2168-9709-15-5-252-b15","series-title":"Ment Health Clin","first-page":"263","article-title":"Loxapine in patient with clozapine-resistant psychosis","volume":"11","author":"Erley","year":"2021","unstructured":"Erley J,\nGoldsborough S,\nVandenBerg A,\nAudu A. Loxapine in patient with clozapine-resistant psychosis. Ment Health Clin. 2021;11(4):263-6. DOI: 10.9740\/mhc.2021.07.263"},{"issue":"1","key":"i2168-9709-15-5-252-b16","series-title":"Cureus","first-page":"e12919","article-title":"Considering loxapine instead of clozapine: a case series and literature review","volume":"13","author":"Shrestha","year":"2021","unstructured":"Shrestha S,\nAgha RS,\nKhan Z,\nShah K,\nJain S. Considering loxapine instead of clozapine: a case series and literature review. Cureus. 2021;13(1):e12919. DOI: 10.7759\/cureus.12919"}],"container-title":["Mental Health Clinician"],"original-title":[],"link":[{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/15\/5\/article-p252.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/15\/5\/article-p252.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/15\/5\/article-p252.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:32:19Z","timestamp":1759365139000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/15\/5\/article-p252.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":16,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.9740\/mhc.2025.10.252","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}